Evolus (EOLS) Amortization of Deferred Charges (2018 - 2026)
Evolus (EOLS) posted Amortization of Deferred Charges of $361000.0 for Q1 2026, up 7.76% on a QoQ basis from $335000.0 in Q4 2025, and up 37.26% year-over-year from $263000.0 in Q1 2025.
Evolus (EOLS) Amortization of Deferred Charges (2018 - 2026) Analysis & Trends
Evolus' Amortization of Deferred Charges history runs 9 years deep, the most recent figure standing at $361000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 37.26% year-over-year to $361000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 5.78% YoY) and the FY2025 annual result came in at $1.2 million, up 7.85% from the prior year.
- Amortization of Deferred Charges was $361000.0 for Q1 2026 at Evolus, up from $335000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $662000.0 in Q4 2024 and bottomed at $13000.0 in Q3 2023.
- A 5-year average of $250235.3 and a median of $263000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges plunged 86.75% — and 2024, when it soared 1315.38%.
- Evolus' Amortization of Deferred Charges stood at $202000.0 in 2022, then retreated by 28.71% to $144000.0 in 2023, then jumped by 359.72% to $662000.0 in 2024, then sank by 49.4% to $335000.0 in 2025, then advanced by 7.76% to $361000.0 in 2026.
- Business Quant data shows EOLS's Amortization of Deferred Charges at $361000.0 in Q1 2026, $335000.0 in Q4 2025, and $292000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 361,000.00 |
| Mar 31, 2026 | 361,000.00 |
| Dec 31, 2025 | 335,000.00 |
| Dec 31, 2025 | 335,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 347,000.00 |
| Jun 30, 2025 | 347,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Dec 31, 2024 | 662,000.00 |
| Dec 31, 2024 | 662,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 153,000.00 |
| Jun 30, 2024 | 153,000.00 |
| Mar 31, 2024 | 148,000.00 |
| Mar 31, 2024 | 148,000.00 |
| Dec 31, 2023 | 144,000.00 |
| Dec 31, 2023 | 144,000.00 |